u 77779 has been researched along with Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Berg, K; Hammond, LA; Patnaik, A; Rizzo, J; Rowinsky, EK; Schwartz, GH; Von Hoff, DD | 1 |
Adjei, AA; Ames, MM; Atherton, P; Bagniewski, PG; Erlichman, C; Goldberg, RM; Pitot, HC; Rayson, D; Reid, JM; Rubin, J; Sloan, JA | 1 |
2 trial(s) available for u 77779 and Neoplasms
Article | Year |
---|---|
A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; DNA; Dose-Response Relationship, Drug; Drug Administration Schedule; Duocarmycins; Female; Humans; Indoles; Intercalating Agents; Male; Middle Aged; Neoplasms; Urea | 2003 |
A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Biological Availability; Duocarmycins; Female; Humans; Indoles; Injections, Intravenous; Leukocyte Count; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutrophils; Urea | 2002 |